Grant: Operating Grant
Ottawa Hospital Research Institute
$487,377.00
A Pilot Study Assessing Feasibility of a Randomized, Placebo-controlled Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism (pilot PROSPER Trial: PostpaRtum PrOphylaxiS for PE Randomized Control Trial).
EF 2009-10
Résumé
The weeks after delivery are known to be a time of high risk for women to develop blood clots in their legs and lungs. Certain women are at particularly high risk due to factors related to their pregnancy, delivery, lifestyle or heredity. We plan to conduct a pilot study to determine the feasibility of a large drug trial with this group of women. The trial will compare the effectiveness of daily blood thinners (low molecular weight heparin) versus placebo, taken for 3 weeks after delivery, at preventing blood clots during this period.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
202231
Name
Rodger Marc A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
A Pilot Study Assessing Feasibility of a Randomized, Placebo-controlled Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism (pilot PROSPER Trial: PostpaRtum PrOphylaxiS for PE Randomized Control Trial).
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$487,377
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
High Risk; Low Molecular Weight Heparin; Pilot Study; Placebo Control; Postpartum; Prophylaxis; Randomized Controlled Trial; Rct; Venous Thromboembolic Disease
Abstract
The weeks after delivery are known to be a time of high risk for women to develop blood clots in their legs and lungs. Certain women are at particularly high risk due to factors related to their pregnancy, delivery, lifestyle or heredity. We plan to conduct a pilot study to determine the feasibility of a large drug trial with this group of women. The trial will compare the effectiveness of daily blood thinners (low molecular weight heparin) versus placebo, taken for 3 weeks after delivery, at preventing blood clots during this period.
Competitiondate
201003
Approvedterm2
1 yr 6 mths
Pinamesdelim
Rodger, Marc A
Approvedterm
1 an 6 mois
Cihrcontribution2
~ $487,377~ $0~
